Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11989-94. doi: 10.1073/pnas.1101478108. Epub 2011 Jun 29.

A yeast-based assay identifies drugs active against human mitochondrial disorders.

Author information

  • 1INSERM U613; Université de Brest, Faculté de Médecine et des Sciences de la Santé; Etablissement Français du Sang (EFS) Bretagne; Centre Hospitalier Régional Universitaire Brest, Hop Morvan, Laboratoire de Génétique Moléculaire, F-29200 Brest, France.

Abstract

Due to the lack of relevant animal models, development of effective treatments for human mitochondrial diseases has been limited. Here we establish a rapid, yeast-based assay to screen for drugs active against human inherited mitochondrial diseases affecting ATP synthase, in particular NARP (neuropathy, ataxia, and retinitis pigmentosa) syndrome. This method is based on the conservation of mitochondrial function from yeast to human, on the unique ability of yeast to survive without production of ATP by oxidative phosphorylation, and on the amenability of the yeast mitochondrial genome to site-directed mutagenesis. Our method identifies chlorhexidine by screening a chemical library and oleate through a candidate approach. We show that these molecules rescue a number of phenotypes resulting from mutations affecting ATP synthase in yeast. These compounds are also active on human cybrid cells derived from NARP patients. These results validate our method as an effective high-throughput screening approach to identify drugs active in the treatment of human ATP synthase disorders and suggest that this type of method could be applied to other mitochondrial diseases.

PMID:
21715656
[PubMed - indexed for MEDLINE]
PMCID:
PMC3141935
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk